These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8707761)

  • 1. Chemotherapy and neutropenia.
    Kim SK; Demetri GD
    Hematol Oncol Clin North Am; 1996 Apr; 10(2):377-95. PubMed ID: 8707761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal models for evaluating the myelosuppressive effects of cancer chemotherapeutic agents.
    Schurig JE; Schlein A; Florczyk AP; Farwell AR; Bradner WT
    Exp Hematol; 1985; 13 Suppl 16():101-5. PubMed ID: 3987834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC
    Drugs; 2002; 62 Suppl 1():1-15. PubMed ID: 12479591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood neutrophil increment after a single injection of rhG-CSF or rhGM-CSF correlates with marrow cellularity and may predict the grade of neutropenia after chemotherapy.
    Hansen PB; Johnsen HE; Ralfkiaer E; Hansen NE
    Br J Haematol; 1993 Aug; 84(4):581-5. PubMed ID: 7692936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of granulocyte-macrophage colony-stimulating factor on neutropenia and related morbidity induced by myelotoxic chemotherapy.
    Herrmann F; Schulz G; Wieser M; Kolbe K; Nicolay U; Noack M; Lindemann A; Mertelsmann R
    Am J Med; 1990 Jun; 88(6):619-24. PubMed ID: 2189305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prevention and treatment of febrile neutropenia].
    Montemurro F; Gallicchio M; Aglietta M
    Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing hematologic toxicities in the oncology patient.
    Montoya L
    J Infus Nurs; 2007; 30(3):168-72. PubMed ID: 17505218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil dynamics in response to chemotherapy and G-CSF.
    Zhuge C; Lei J; Mackey MC
    J Theor Biol; 2012 Jan; 293():111-20. PubMed ID: 22037060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
    Dunn CJ; Goa KL
    Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy dose intensity and quality cancer care.
    Lyman GH
    Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):16-25. PubMed ID: 17370925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreated baseline neutrophil count and chemotherapy-induced neutropenia may be conveniently available as prognostic biomarkers in advanced gastric cancer.
    Chen Z; Chen W; Wang J; Zhu M; Zhuang Z
    Intern Med J; 2015 Aug; 45(8):854-9. PubMed ID: 25871806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of hematopoietic growth factors in oncology].
    Delmer A; Zittoun R
    Bull Cancer; 1991; 78(2):115-31. PubMed ID: 2036483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The present and future of hematopoietic cytokines in clinical practice.
    George MJ
    Stem Cells; 1994; 12 Suppl 1():249-55. PubMed ID: 7696964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth factor use in medication-induced hematologic toxicity.
    Miller RC; Steinbach A
    J Pharm Pract; 2014 Oct; 27(5):453-60. PubMed ID: 25249588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose reductions and delays: limitations of myelosuppressive chemotherapy.
    Cairo MS
    Oncology (Williston Park); 2000 Sep; 14(9 Suppl 8):21-31. PubMed ID: 11033835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized study of dose or schedule modification of granulocyte colony-stimulating factor in platinum-based chemotherapy for elderly patients with lung cancer.
    Oshita F; Yamada K; Nomura I; Tanaka G; Ikehara M; Noda K
    Oncol Rep; 2001; 8(4):861-6. PubMed ID: 11410799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mouse as a model for predicting the myelosuppressive effects of anticancer drugs.
    Schurig JE; Florczyk AP; Bradner WT
    Cancer Chemother Pharmacol; 1986; 16(3):243-6. PubMed ID: 3698166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.